These data support less restrictive clinical trial eligibility criteria for those with metastatic NSCLC. This is especially true regarding both targeted therapy and immunotherapy treatment regimens.
Robin High, MA
Advertisement
Articles by Robin High, MA
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
Choosing Between Approved Frontline Metastatic Pancreatic Cancer Regimens
2
Lenvatinib/Pembrolizumab Shows Promise After IO Progression in GYN Cancers
3
FDA Issues Another CRL for Amorphous Dasatinib Receives in CML and ALL
4
How Have Bispecific Antibodies Evolved in Multiple Myeloma?
5